Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21776969 | 0.75 | CES1 (0.37) | CES1BRD4 | |
| SCHEMBL19932028 | 0.71 | CES1 (0.39) | CES1ADRA2AADRA1ADRD2 | |
| SCHEMBL19932031 | 0.71 | MEN1 (0.37) | CES1ADRA2AADRA1ADRD2HTR2A | |
| SCHEMBL9722649 | 0.70 | BRD4 (0.38) | CES1BRD4KDM4EALDH1A1HPGD | |
| SCHEMBL8832281 | 0.68 | ALDH1A1 (0.42) | BRD4KDM4EALDH1A1HPGD | |
| SCHEMBL30192941 | 0.67 | ALDH1A1 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL2431135 | 0.67 | ALDH1A1 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL24169466 | 0.67 | BCL2L1 (0.36) | CES1 | |
| SCHEMBL834190 | 0.67 | SOS1 (0.41) | SOS1ADRA2AADRA1AHTR2AHTR2C | |
| SCHEMBL835800 | 0.66 | PTPRF (0.39) | KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378118-B2 | Pyrazole-based thyroid receptor compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2013-02-19 | — | — | US | disclosed |
| US-20120202816-A1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS, LTD. (IN) | 2012-08-09 | — | — | US | disclosed |
| US-8143424-B2 | Thyroid like compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2012-03-27 | — | — | US | disclosed |
| EP-2061766-B1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2010-08-18 | — | — | EP | disclosed |
| US-20100168110-A1 | Novel Compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-07-01 | — | — | US | disclosed |
| EP-2061766-A2 | NOVEL COMPOUNDS | Torrent Pharmaceuticals Ltd (IN) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008149379-A2 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202816-A1 | NOVEL COMPOUNDS | TSHR, THRB, GPR119 | SOS1 4032/4885CES1 183/4885BRD4 691/4885 |
| US-20100168110-A1 | Novel Compounds | TSHR, THRB, GPR119 | SOS1 4032/4885CES1 183/4885BRD4 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.